国际眼科纵览 ›› 2023, Vol. 47 ›› Issue (1): 68-73.doi: 10.3760/ cma.j.issn.1673-5803.2023.01.013

• 综述 • 上一篇    下一篇

雷帕霉素在眼科疾病中的研究及应用

丁雪萌 刘茜 陈培培 管怀进   

  1. 南通大学附属医院眼科,江苏南通 226001
  • 收稿日期:2022-05-15 出版日期:2023-02-22 发布日期:2023-03-11
  • 通讯作者: 管怀进,Email:guanhjeye@163.com E-mail:guanhjeye@163.com
  • 基金资助:
    国家重点研发计划项目(2017YFA0701304);国家自然科学基金(82171038)

Research and application of rapamycin on ophthalmic diseases

Ding Xuemeng, Liu Xi, Chen Peipei, Guan Huaijin   

  1. Department of Ophthalmology, Affiliated Hospital of Nantong University, Nantong 226001, China
  • Received:2022-05-15 Online:2023-02-22 Published:2023-03-11
  • Contact: Guan Huaijin, Email: guanhjeye@163.com E-mail:guanhjeye@163.com
  • Supported by:
    National Key R&D Program of China(2017YFA0701304); National Natural Science Foundation of China(82171038)

摘要: 哺乳动物雷帕霉素靶蛋白(mTOR)属丝氨酸-苏氨酸激酶,在调节细胞生长、增生、代谢、自噬和衰老方面发挥着重要作用。雷帕霉素(rapamycin, RAPA)是大环内酯类的免疫抑制剂,因毒性低且具有高效的免疫抑制效应而得以广泛应用。近期研究表明,雷帕霉素在眼科多种疾病的治疗中具有应用潜力,尤其是角膜炎、葡萄膜炎、白内障、青光眼以及眼底病等。雷帕霉素在免疫抑制、抗新生血管形成、抗纤维化、神经保护等方面的作用体现了在眼科疾病中的应用前景。(国际眼科纵览,2023, 47:68-73)

关键词: 雷帕霉素, 哺乳动物雷帕霉素靶蛋白, 真菌性角膜炎, 视网膜色素变性

Abstract: The mammalian target of rapamycin (mTOR) is a serine-threonine kinase that has important regulatory effects on cell growth, proliferation, metabolism, autophagy and ageing. Rapamycin (RAPA) is a macrolide immunosuppressant that is widely used after organ transplantation due to its low toxicity and highly potent immunosuppressive effects. Recent studies have shown that rapamycin has application potential in the treatment of various ophthalmological diseases, especially in anti-transplant rejection after corneal transplantation, keratitis, uveitis, cataracts, glaucoma and ocular fundus diseases. The role of rapamycin in immunosuppression, anti-angiogenesis, anti-fibrosis, neuroprotection reflects the promise of its application in ophthalmic diseases. (Int Rev Ophthalmol, 2023, 47: 68-73)

Key words: rapamycin, eye diseases, mTOR, fungal keratitis, retinitis pigmentosa